







From Farm to Pharma

MMJ Bioscience and PhytoTech Medical
Inaugural Roadshow: Introduction to MMJ-PhytoTech
April 2015

MMJ PhytoTech A Merger of Equals – Overview



	Overview		Equity Value ⁽¹⁾ (A\$m)
	<ul style="list-style-type: none"> 1st ASX Listed MC Company Israel-based R&D Strategy 	<ul style="list-style-type: none"> Significant Pharma Experience Public, Strong Financial Position 	\$21
	<ul style="list-style-type: none"> Integrated MC Platform On Track to MMPR⁽¹⁾ Licensing 	<ul style="list-style-type: none"> Legal MC Production Imminent Euro Pharma-Initiative: Satipharm 	\$21
	<ul style="list-style-type: none"> Fully financed ``Farm to Pharma`` 	<ul style="list-style-type: none"> A multinational vertically integrated Medical Cannabis (MC) company 	\$42
Indicative Merger Timeline			

Note 1: This is based on the official ASX closing price for PYL on Friday 17th April, 2015, of A\$0.31. For PYL's shares outstanding, 20mm performance rights are assumed to have been converted into ordinary shares.

MMJ PhytoTech A Merger of Equals – Strategic Rationale



Strategic Rationale

Creates: Fully-Integrated & Global Cannabis-Focused Bioscience Platform


Strengthens: “Farm to Pharma” Closed Loop Supply Chain, Diversifies Globally

Complements: Cash Flows and Assets Complementary, High Synergy Potential

De-risks: Near- and Mid-term Cash Flow from MMJ, Long-term Value from Both

MMJ + PhytoTech: A Complementary Merger

Illustrative Farm to Pharma Continuum



1 Unique Global Cannabis Platform



Established Footprint in Key Markets Internationally

2 Spanning “Farm to Pharma”



*Supply Chain
Expertise
Products
Value*



Vertically Integrated, Global Platform



Near-Term Value Potential




MC Sales
from Duncan



GMP-Produced
CBD Pill Sales





3 In Place and Implemented Today

Long-Term Strategic Vision




4 Foundation for Pharma Evolution

5 “Pipeline” of Value Catalysts: Near-, Mid-, and Long-Term

Subsidiary	Near-term Potential Catalysts	Mid-term Potential Catalysts	Long-term Potential Catalysts
	MMPR License Ramp up to 700kg/year ⁽¹⁾	Lucky Lake 11 tpa ⁽²⁾ Export / Whole Opportunities Consolidation Strategy New Jurisdictions	Self Supplier Mktg. & Dist. Efficiencies Further Consolidation
	CDB Dietary Supplement Sales	Expansion of CBD Production Seed Production Fast Track PYL R&D	Large Supplier of Cannabis-based Pharmaceutical Compounds
	Further Developments with Oral Capsule and Buccal Patch	Clinical Trials Acquisitions In house R&D New Academic Relationships	Drug Approvals Pharmaceutical Sales
	Bolt-on Acquisitions: Agro-Medical or Therapeutics	Organic Opportunities Acquisitions	Pursue Global Growth in Choice Segments

MMJ-PhytoTech's Global Footprint *Strategically Positioned in Select International Jurisdictions*



MMJ – PhytoTech Australia



Australian PubCo
Chairman: Peter Wall
Managing Director: Andreas Gedeon
President: Boaz Wachtel
Board: 3 MMJ / 4 PYL



United Greeneries Canada
Canadian MMPR Applicant
CEO: Mike Hinam




Satipharm Switzerland
European Nutraceutical Manufacturer
CEO: Tomas Edvinsson



PhytoTech Therapeutics Israel
Israeli Pharmaceutical Developer
CEO: Dr. Daphna Heffetz Phd

Supply Chain



Market Sizes

Estimated Size of Select Marijuana Markets

2018 CDN MMPR
C\$0.6 Billion

C\$0.6 Bn

2018 U.S. Legal Mkt
US\$10.2 Billion

US\$10.2 Bn

Global Black Mkt
US\$141 Billion

US\$141 Bn

Global Nutra / Pharmaceutical Markets

2013 Global Nutraceutical
US\$175 Billion

US\$175 Bn



2013 Global Pharmaceutical
US\$916 Billion

US\$916 Bn

Expertise



Products



MMJ & PhytoTech In Place and Implemented Today



2 X

State-of-the-art
Cultivation Facilities in
Western Canada

1 X

Facility in Final Stage
of MMPR Licensing:
The Duncan Facility

12 Tonnes
Per Year

Theoretical MC
Production Capacity of
Both Facilities

700 kg

Estimated 2016 MC
Production from Duncan

78,000 ft²

Combined Area of
Both Facilities

1 X

Facility Owned by
MMJ: Lucky Lake

World Class Partners



Creating World Class Products



Planning on Creating Many More...



Yissum is charged with the commercializing of technology that has been developed and/or researched at the Hebrew University of Jerusalem. They liaise with potential investors and companies and usually keep a royalty as compensation upon successful outcome of a deal.

PhytoTech has entered into agreements that provide for the following products:

- Oral capsule and Buccal products
- Pre-packaged doses of medical cannabis delivered by vaporisation devices




Duncan Facility and Laboratory




- ▲ 16,000 ft² production facility and full quality control laboratory in Duncan, BC:
 - ▶ 9,600 ft² cultivation area
 - ▶ 1,000 ft² clean area
 - ▶ Level 8 security vault
- ▲ \$2.2m facility upgrade to be completed June 2015
- ▲ Facility is finished and awaiting pre-licensing inspection
- ▲ Received "Confirmation of Readiness" letter from Health Canada on April 1st
- ▲ MMJ is currently working at maximum capacity to secure a pre-licensing inspection by late June





Western Canada Facility: Lucky Lake



- ▲ 62,000 ft² modern agricultural facility
- ▲ Comprehensive MMPR application submitted in late march
- ▲ MMJ has received non-binding offers of on the facility at multiples of original purchase price
- ▲ 18-acre site provides MMJ with scalability
 - ▶ +800,000 ft² (2) expansion capacity = 12 similar facilities = 132,000 kg/year additional capacity

TSX-V Listed MMPR Companies

(As At April 16th, 2015)

Company Name		Share Price	Basic Shares Outstanding	FDITM T- method S/O	Equity Value	EV
		\$	M	M	\$M	\$M
<u>Companies Listed on the TSX-V (all figures are in CAD\$)</u>						
Tweed Marijuana Inc.	TSXV:TWD	\$2.03	40.0	40.3	\$81.8	\$53.4
OrganiGram Holdings Inc.	TSXV:OGI	\$0.57	51.0	51.0	\$29.1	\$28.5
Mettrum Health Corp.	TSXV:MT	\$1.92	33.7	34.7	\$66.7	\$40.9
Bedrocan Cannabis Corp.	TSXV:BED	\$0.75	69.2	70.2	\$52.7	\$41.6
Aphria Inc.	TSXV:APH	\$1.16	38.7	39.2	\$45.5	\$33.5
T-Bird Pharma Inc. ⁽¹⁾	TSXV:TPI	\$0.52	46.1	46.5	\$24.2	\$21.2
PharmaCan	TSXV: MJN	\$0.59	32.8	39.5	\$23.3	\$19.7

Note 1: T-bird only has a license to produce contrary to the TSXV listing requirements. When it RTod it had the full distribution license and since had it revoked

MMJ / PhytoTech

Current Capitalisation / Deal Metrics



	Shares	Options	Performance Rights
PYL current issued capital ¹	64,662,050 ²	2,500,000 ³	20,000,000 ⁴
Initial Shares to be issued to MMJ Shareholders ⁷	51,000,000	Nil	Nil
MMJ First Deferred Shares ⁵	8,500,000	Nil	Nil
MMJ Second Deferred Shares ⁶	8,500,000	Nil	Nil
Introduction Fee Shares	2,040,000	Nil	Nil
Total Post Merger	134,702,050	2,500,000	20,000,000

Notes:

1. This assumes no further securities are issued prior to settlement of the merger with MMJ. 23 million shares are escrowed until January 2017 and 7.2 million shares are escrowed until 17 September 2014.
2. This assumes 20,000,000 fully paid ordinary shares have been issued upon conversion of 20,000,000 Class A and Class B Performance Rights that have vested but not yet converted to ordinary shares. These shares will be escrowed until January 2017.
3. Each Option is unquoted and is exercisable at \$0.20 on or before three years from their date of issue. These option are all escrowed until January 2017.
4. This includes 10,000,000 Class C Performance Rights and 10,000,000 Class D Performance Rights on issue which have not vested yet.
5. These shares convert to ordinary PYL shares in the event that MMJ or one of its subsidiaries is granted a licence to produce under the Marihuana for Medical Purposes Regulations in Canada within 12 months of settlement of the merger.
6. These shares convert to ordinary PYL shares in the event that MMJ and its subsidiaries generate at least CAD\$5,000,000 in revenue from operating activities within 36 months of settlement of the merger.
7. All shares issued under the MMJ merger will be escrowed in equal thirds being freely tradeable 3 months, 9 months and 15 months from settlement of the merger respectively.



Peter Wall, LLB. B.Comm M.App Fin. – Independent Chairman

Mr. Wall is a corporate lawyer based in Perth, with over 15 years' experience in advertising on a wide range of corporate and commercial matters. He specialises in mergers and acquisitions, back door listings and all forms of capital market transactions. He also has significant experience in cross border transactions.



Andreas Gedeon, Dipl.-Paed. - Managing Director / Director Appointed by MMJ

Mr. Gedeon, a former Officer in the German Navy, holds a degree in Educational Science from the University of Federal Armed Forces Munich. He is an experienced business man with proven expertise in large-scale and HR intensive projects. His previous areas of work include media production, the food industry, horticulture and commercial construction. As the founder of MMJ, Mr. Gedeon currently oversees the global expansion strategy of the MMJ group and is the designated Managing Director of MMJ/PYL post merger.



Boaz Wachtel, MA – President / Director

Mr. Wachtel is an Israeli medical cannabis pioneer/activist who formulated and assisted the Ministry of Health with the implementation of the National Medical Cannabis Program – one of only three national programs in the world. He is a frequent lecturer and advisor to governments, businesses and NGOs on medical cannabis program formulation, grow operations, international laws and UN drug convention compliance, as well as the founder and former chairman of the Green Leaf Party – a political party for cannabis legalisation/medicalisation, human rights and ecology. He is a former Assistant of Army Attaché at the Israeli Embassy in Washington and a certified clinical research manager.

**Ross McKay (CMA) - Director Appointed by MMJ**

Ross has significant experience in the pharmacy, medical clinic and veterinarian fields and holds a BSc Pharm, Pharmacy degree from UBC. He is the Managing Partner in charge of operations at VetStrategy, a manager of veterinary practices in Canada. Former President of Medicine Shoppe Canada where he oversaw the growth of the chain into a leading independent Canadian pharmacy which, along with Drug Trading Company Ltd., was sold by Katz Group to McKesson Corp. for \$920mm in 2012. Mr. McKay also worked with Save-On-Food and Wal-Mart Canada, helping build out their successful pharmacy divisions in BC and Alberta. He is working to advance the development and execution of MMJ's veterinarian product strategy.

**Dr. Benad Goldwasser, MD MBA – Chairman of PhytoTech Therapeutics, Executive Director PhytoTech Medical**

A well-known MD and serial entrepreneur in Israel. He has founded or co-founded at least nine companies including Vidamed Inc., (acquired by Medtronic after going public on NASDAQ); Medinol Ltd., (partnered with Boston Scientific for marketing and sales of its coronary stents), RITA Medical (public on NASDAQ) and Optonol (acquired by Alcon). He was a seed investor in Medcon Ltd. (acquired by McKesson Corp after going public on the Tel Aviv Stock Exchange) a company in medical IT. That went public on the Tel Aviv Stock exchange and was later acquired by McKesson Corp. Benad is the author and co-author of over 120 original articles and 19 book chapters in books published in the field of Urology and was the co-editor of two books published in the field of reconstructive urology.

**Winton Willesee, CPA – Non Executive Director**

Mr. Willesee is an experienced company director with a broad range of skills and experience in strategy, company development, corporate governance, company public listing, merger and acquisition transactions and corporate finance. He has considerable experience with ASX listed companies and has been involved with many successful ventures from early stage through large capital development projects. He holds formal qualifications in economics, finance, accounting, education and governance. He is a fellow of the Financial Services Institute of Australia, a Member of the Australian Institute of Company Directors, a member of CPA Australia and a Chartered Secretary.

**Jason Bednar, B.Comm, CA, Director Appointed by MMJ**

Mr. Bednar is a Chartered Accountant with more than 18 years of direct professional experience in senior financial capacities of TSX, TSXV, AMEX, Australian ASX and Colombian BVC listed E&P companies. Mr. Bednar has served as the CFO of several internationally focused E&P companies including being the founding Chief Financial Officer of Pan Orient Energy Corp., a South East Asia Exploration company until 2009, during which time they grew to a TSXV 50 company operating 15,000 bbl/d and a market cap of \$800mm. He has sat on the board of directors of numerous E&P companies including the past Chairman of Gallic Energy Ltd, who during his tenure became a TSXV 50 company. He is currently Chairman of the Audit Committee of Canacol Energy Ltd (TSX and BVC listed), and also sits in a similar capacity at Mobious Resources Inc.

**Dr. Daphna Heffetz, PhD – CEO PhytoTech Therapeutics**

Dr. Heffetz's has over 20 years of experience in establishing and growing Biotech and Mediatec technology based companies. Her most recent position was Chief Executive Officer with Alon MedTech Ventures, an Israeli medical device and technology accelerator. In 2000 she founded TransPharma Medical, one of the most promising active transdermal drug delivery companies in the world. Dr. Daphna Heffetz holds MSc and PhD degrees in biochemistry and a Post-Doctoral Fellow in molecular biology from the Weimann Institute of Science.

**L. Michael Hinam, CEO United Greeneries**

Regulatory professional with over 30 years experience, most of which was spent working in government and community relations. Mr. Hinam was part of a small team of professionals that developed and expanded the Community Gaming Center model in the Province of British Columbia, increasing net revenue over a 7 year period from \$50 million to \$350 million annually. Mr. Hinam is in charge of MMPR licensing and will oversee Canadian production and facilities.

**Devon Brown (CPA), CFO United Greeneries**

Chartered Professional Accountant with significant experience in highly regulated industries. Previously, he worked for Sr. Business Analyst at BC Lottery Corp. and Sr. Business Analyst at Great Canadian Gaming. Mr. Brown is actively involved in the financial management of projects including the upgrade of the Duncan Facility. Mr. Brown has a BA in English Literature from the University of Regina.